A team of researchers from the Rice Biotech Launch Pad at Rice University in Houston developed the implantable “cytokine ...

A team of researchers from the Rice Biotech Launch Pad at Rice University has developed an implantable "cytokine factory" that safely triggers potent immune responses against hard-to-treat cancers, ...

These results demonstrate that the axis of interleukin 12 and gamma interferon provides a survival advantage in vascularized xenografts by delaying or preventing acute vascular rejection caused by ...

Polymer-coated nanoparticles loaded with therapeutic drugs show significant promise for cancer treatment, including ovarian ...

One such messenger is interleukin-12 (IL-12). Through meticulous analyses, research teams led by Professor Frank Heppner, Director of the Department of Neuropathology at Charité ...

D epartment of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting interleukin (IL)-12, IL-23, or IL-17 were associated with a lower rate of ...

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

IL-18BPR is a modified version of Interleukin-18 that exhibits effective ... improve treatment outcomes by combining IL-18BPR with IL-12. Sonnet is focused on developing targeted immunotherapeutic ...

Biologics targeting interleukin (IL)-12, IL-23, or IL-17 are linked to a 35% lower rate of serious infections in older adults with psoriatic disease compared to other treatments.